Brokers Set Expectations for Legend Biotech Q1 Earnings

Legend Biotech Co. (NASDAQ:LEGN - Free Report) - Investment analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for Legend Biotech in a note issued to investors on Wednesday, April 16th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($0.17) per share for the quarter, up from their previous estimate of ($0.18). HC Wainwright has a "Buy" rating and a $75.00 price objective on the stock. The consensus estimate for Legend Biotech's current full-year earnings is ($1.31) per share.

Legend Biotech (NASDAQ:LEGN - Get Free Report) last released its quarterly earnings data on Tuesday, March 11th. The company reported $0.07 earnings per share for the quarter, beating analysts' consensus estimates of ($0.39) by $0.46. Legend Biotech had a negative net margin of 66.92% and a negative return on equity of 29.69%. The business had revenue of $186.50 million during the quarter, compared to analyst estimates of $179.00 million. During the same period last year, the business earned ($0.40) EPS. Legend Biotech's revenue was up 134.6% compared to the same quarter last year.

Other research analysts have also recently issued research reports about the company. Royal Bank of Canada restated an "outperform" rating and issued a $84.00 price target on shares of Legend Biotech in a research note on Tuesday. Morgan Stanley lowered their target price on shares of Legend Biotech from $82.00 to $80.00 and set an "overweight" rating on the stock in a research note on Monday, March 17th. Guggenheim reiterated a "neutral" rating on shares of Legend Biotech in a research note on Wednesday, March 12th. Finally, Piper Sandler restated an "overweight" rating and issued a $78.00 target price on shares of Legend Biotech in a report on Monday, December 30th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $78.82.

Legend Biotech Stock Up 6.9 %

NASDAQ LEGN traded up $2.24 during mid-day trading on Friday, reaching $34.48. The stock had a trading volume of 1,346,480 shares, compared to its average volume of 1,238,057. The company has a fifty day moving average price of $34.96 and a 200 day moving average price of $37.53. The company has a debt-to-equity ratio of 0.27, a current ratio of 4.98 and a quick ratio of 4.90. Legend Biotech has a 1 year low of $29.27 and a 1 year high of $60.87. The stock has a market cap of $6.33 billion, a PE ratio of -36.29 and a beta of 0.21.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in LEGN. GAMMA Investing LLC lifted its holdings in Legend Biotech by 145.4% during the first quarter. GAMMA Investing LLC now owns 1,291 shares of the company's stock valued at $44,000 after purchasing an additional 765 shares in the last quarter. Signaturefd LLC increased its stake in Legend Biotech by 1,052.7% in the 4th quarter. Signaturefd LLC now owns 1,729 shares of the company's stock worth $56,000 after buying an additional 1,579 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in Legend Biotech during the fourth quarter valued at about $56,000. Shell Asset Management Co. lifted its position in shares of Legend Biotech by 62.0% in the fourth quarter. Shell Asset Management Co. now owns 2,090 shares of the company's stock valued at $68,000 after acquiring an additional 800 shares in the last quarter. Finally, OFI Invest Asset Management purchased a new position in shares of Legend Biotech in the fourth quarter valued at about $77,000. 70.89% of the stock is owned by hedge funds and other institutional investors.

Legend Biotech Company Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).